Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Thomson Reuters Corp — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B), while Thomson Reuters Corp trades at $100.95 (market cap $43.21B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and Thomson Reuters Corp for 63 Days on average.
| TAK | TRI | |
|---|---|---|
Market Cap | $58.16B | $43.21B |
Volume | 2,467,530 | 1,017,653 |
Sector | Health | Industrials |
52-Week High | $19.05 | $163.45 |
52-Week Low | $13.23 | $76.55 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $86.04B | $45.82B |
Dividend Yield | 3.36% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Thomson Reuters (TRI) stock trades at $101.55, up 3.53% today, showing strong momentum amid positive technical signals and fundamental strength. The company demonstrates robust profitability with 75.7% gross margins and 21.22% net income margins, supported by 10% organic growth in core businesses. Recent developments include the successful divestment of its printing unit and the launch of proprietary AI technology, positioning TRI for continued growth in the legal and professional information markets.
With analyst consensus pointing to 31% upside to the $133.25 price target and strong institutional buying, TRI presents a compelling growth opportunity. However, investors should monitor execution risks around AI integration and potential cybersecurity vulnerabilities following recent incidents. The stock's current valuation at 26.16x P/E appears reasonable given the company's recurring revenue model and market leadership position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
